Archives: Seminars

The US Regulator: Extended session with Q&A

We are pleased to welcome Dr Brian King, Director of the Center for Tobacco Products at the FDA. This will be an extended session and allow time for questions and answers.  The final topic will be confirmed soon.

CLOSING KEYNOTE: What Constitutes Success? A Dialogue on the “End State”

In this extended closing keynote session, Tom Glynn will moderate a dialogue with Cliff Douglas and Mitch Zeller on the potential “End State” for tobacco control efforts.  Rather than focusing on the pros or cons of various harm reduction approaches, Cliff and Mitch will describe the differences between potentially competing visions for what “success” looks… Read more »

An international standard for vaping health risks research

To accelerate understanding of the contribution vaping can make to endgame strategies, we need more research. However, the quality of the research is critically important and this is particularly important when funding is limited. The UK’s Office for Health Improvement and Disparities (OHID) e-cigarette health risk review findings were constrained largely because of the methodological… Read more »

Tobacco Harm Reduction: What will (does) success look like?

From national goals (e.g., Healthy People 2030 in the US) to various formulations of so-called endgame strategies, concerned entities (governments, NGO’s) have described what might constitute success in terms of controlling and/or ending the tobacco and/or nicotine “epidemic.” Not surprisingly, such goals are not always clearly articulated, they change over time, and the processes by… Read more »

E-cigarettes and mental health disorders: Opportunity or Concern?

Individuals with mental health or substance use disorders have disproportionately higher prevalence of smoking, greater levels of nicotine dependence, and worse health and quality of life outcomes than people without these conditions. Smokers with these disorders also have lower success with smoking cessation, even with evidence-based treatments. Thus, they remain a high priority population for… Read more »